Search Results - "pharmacodynamics"

Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total by John Hood, Ignacio González-García, Nicholas White, Leeron Marshall, Vincent F. S. Dubois, Paolo Vicini, Paul G. Baverel

Connect to this object online.

Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP) by Suein Choi, Seunghoon Han, Sangil Jeon, Dong-Seok Yim

Connect to this object online.

A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects by Leilei Zhu, Rong Shi, Tongfang Zhao, Yujie Ye, Jie Tang, Yihui Hu, Peng Peng, Dong Wang, Clement Chong, Guolin Xu, Shui‐on Leung, Wei'an Yuan

Connect to this object online.

Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis by Aaron Heffernan, Jowana Alawie, Steven C Wallis, Saiyuri Naicker, Santosh Adiraju, Jason A. Roberts, Fekade Bruck Sime

Connect to this object online.

Evaluation of pharmacokinetics and pharmacodynamics relationships for Salvianolic Acid B micro-porous osmotic pump pellets in angina pectoris rabbit by Shu-Ling Kan, Jin Li, Jian-Ping Liu, Hong-Liang He, Wen-Jing Zhang

Connect to this object online.

Optimizing Antibiotic Therapy for <i>Stenotrophomonas maltophilia</i> Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach by Helena Barrasa, Miguel Angel Morán, Leire Fernández-Ciriza, Arantxa Isla, María Ángeles Solinís, Andrés Canut-Blasco, Alicia Rodríguez-Gascón

Connect to this object online.

A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against Streptococcus suis by Kun Mi, Kun Mi, Lei Sun, Lei Sun, Lan Zhang, Lan Zhang, Aoran Tang, Aoran Tang, Xiaoyuan Tian, Xiaoyuan Tian, Yixuan Hou, Yixuan Hou, Lingling Sun, Lingli Huang, Lingli Huang, Lingli Huang

Connect to this object online.

Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study by Andrew Gewitz, Jeanne Mendell, Yuhuan Wang, Charles Harris, Benjamin A. Olenchock, Simona Podgrabinska, Wenjun Zheng, An Zhao, Hao Pan, Frédéric Vanhoutte, John D. Davis

Connect to this object online.

Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia by Noriyuki Ishihara, Nobuhiro Nishimura, Kazuro Ikawa, Fumi Karino, Kiyotaka Miura, Hiroki Tamaki, Takahisa Yano, Takeshi Isobe, Norifumi Morikawa, Kohji Naora

Connect to this object online.

Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling by Keheng Wu, Xue Li, Zhou Zhou, Youni Zhao, Mei Su, Zhuo Cheng, Xinyi Wu, Zhijun Huang, Xiong Jin, Jingxi Li, Mengjun Zhang, Jack Liu, Bo Liu

Connect to this object online.

Pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats by Bruna Bernar Dias, Fernando Carreño, Victória Etges Helfer, Laura Ben Olivo, Keli Jaqueline Staudt, Karina Paese, Fabiano Barreto, Fabíola Schons Meyer, Ana Paula Herrmann, Sílvia Stanisçuaski Guterres, Stela Maris Kuze Rates, Bibiana Verlindo deAraújo, Iñaki F. Trocóniz, Teresa Dalla Costa

Connect to this object online.

Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson's Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation by Narendar Dudhipala, Thirupathi Gorre

Connect to this object online.

Development of Bisphosphonate-Conjugated Antibiotics to Overcome Pharmacodynamic Limitations of Local Therapy: Initial Results with Carbamate Linked Sitafloxacin and Tedizolid by Emmanuela Adjei-Sowah, Yue Peng, Jason Weeks, Jennifer H. Jonason, Karen L. de Mesy Bentley, Elysia Masters, Yugo Morita, Gowrishankar Muthukrishnan, Philip Cherian, X. Eric Hu, Charles E. McKenna, Frank H. Ebetino, Shuting Sun, Edward M. Schwarz, Chao Xie

Connect to this object online.

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials by Matthew P. Kosloski, Emma Guttman‐Yassky, Michael J. Cork, Margitta Worm, Dong‐Ho Nahm, Xiaoping Zhu, Marcella K. Ruddy, Sivan Harel, Mohamed A. Kamal, Hélène Goulaouic, Christine R. Xu, Elena Avetisova, John D. Davis, Michael C. Nivens, Arsalan Shabbir, Allen Radin

Connect to this object online.

Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing by Eveline E. Roelofsen, Brenda C. M. de Winter, Heleen van der Spek, Susan Snijders, Birgit C. P. Koch, Sanne van den Berg, Anouk E. Muller

Connect to this object online.

Prediction of the Drug-Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model by Zhuodu Wei, Hyeon-Cheol Jeong, Min-Gul Kim, Kwang-Hee Shin

Connect to this object online.

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis by Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, Ronda Rippley, A. Thomas DiCioccio

Connect to this object online.

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics by Mohamed A. Kamal, Robert Dingman, Claire Q. Wang, Ching‐Ha Lai, Manoj Rajadhyaksha, Michelle DeVeaux, Jamie M. Orengo, Allen Radin, John D. Davis

Connect to this object online.

Mechanistic pharmacokinetic-pharmacodynamic modeling and simulations of naloxone auto‐injector 10 mg reversal of opioid‐induced respiratory depression by Tae Eun Yang, Francesca Del Bene, Silvia Maria Lavezzi, Laura Iavarone, Jianping Zhang, Joseph Kim, Breanne Gjurich, Catherine Kessler

Connect to this object online.

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168) by Timothy D. Owens, Patrick F. Smith, Andrew Redfern, Yan Xing, Jin Shu, Dane E. Karr, Sonja Hartmann, Michelle R. Francesco, Claire L. Langrish, Philip A. Nunn, Steven G. Gourlay

Connect to this object online.